Insmed's Investigational Treatment for Skin Disease Falls Short in Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Source: stocktwits
Trial Results: Insmed's mid-stage study evaluating brensocatib in adult patients with moderate to severe hidradenitis suppurativa failed to meet its primary and secondary endpoints.
Drug Tolerance: Despite the trial's failure, the drug was reported to be well tolerated among participants.
Future Development: Insmed announced plans to discontinue the development of brensocatib for hidradenitis suppurativa.
Condition Overview: Hidradenitis suppurativa is a chronic, non-contagious inflammatory skin condition characterized by painful, recurring lumps and abscesses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INSM
Wall Street analysts forecast INSM stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 96.720
Low
162.00
Averages
219.50
High
263.00
Current: 96.720
Low
162.00
Averages
219.50
High
263.00
About INSM
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Market Rally: US stocks extended Thursday's rally on Friday, with the S&P 500 rising 0.50%, the Dow Jones up 0.70%, and the Nasdaq 100 increasing by 0.64%, reflecting investor optimism about a potential interim peace agreement between the US and Iran.
- Consumer Confidence Boost: The University of Michigan's Consumer Sentiment Index rose by 4.1 to 48.9 in June, surpassing expectations of 46.0, indicating a rebound in consumer confidence that could stimulate spending and support economic growth.
- Oil Price Decline: WTI crude oil prices fell 3.23% on Friday amid hopes for a US-Iran agreement, which may lower transportation costs and positively impact fuel-dependent sectors like airlines.
- Strong IPO Performance: SpaceX closed at $161 per share on Friday, up 19% from Thursday's IPO price of $135, indicating robust market demand and potentially fostering positive sentiment for upcoming AI company IPOs.
See More
- Market Enthusiasm: SpaceX's IPO closed at $161 per share, giving it a market value of approximately $2.1 trillion, capturing significant attention from both Wall Street and Main Street, indicating strong investor interest in emerging tech companies.
- Opportunities for AI Firms: Cramer highlighted that SpaceX's success could encourage other companies, particularly in the AI sector like Anthropic, to quickly enter the market for funding, thereby accelerating their technology development and market expansion.
- Oil Prices and Inflation: Cramer noted that developments in the Middle East could impact oil prices, suggesting that a lasting peace could lead to lower oil prices, which would help alleviate inflationary pressures and create a favorable environment for economic recovery.
- Future Market Outlook: Cramer believes that SpaceX's successful debut supports market sentiment, indicating a potentially positive market performance in the upcoming week, especially with the approaching Federal Reserve meeting and economic data releases.
See More
- Successful IPO of SpaceX: SpaceX's debut at $161 per share, valuing the company at approximately $2.1 trillion, injects confidence into the market and may encourage more AI-related firms like Anthropic to pursue IPOs.
- Positive Market Reaction: Cramer notes that SpaceX's success could prompt companies like Microsoft, Meta, and Amazon to sell stock to fund their AI initiatives, reflecting strong market interest and potential growth in AI investments.
- Economic Indicators to Watch: Cramer advises investors to pay attention to upcoming housing starts and retail sales data, as these metrics will provide crucial insights for the Federal Reserve's interest rate decisions, especially amid signs of economic slowdown.
- Geopolitical Impact: Cramer highlights that developments in the Middle East could affect oil prices, suggesting that a lasting peace could lead to lower oil prices, which would help alleviate inflationary pressures and create a more favorable environment for the market.
See More
- Market Rebound: The S&P 500 index rose by 0.58%, the Dow Jones Industrial Average increased by 0.91%, and the Nasdaq 100 index climbed by 0.64%, reflecting market optimism regarding a potential US-Iran peace agreement that could end military hostilities and reopen oil exports through the Strait of Hormuz.
- Consumer Confidence Boost: The University of Michigan's Consumer Sentiment Index increased by 4.1 to 48.9, surpassing expectations of 46.0, indicating a rise in consumer confidence that may stimulate spending and drive economic growth.
- Strong IPO Performance: SpaceX's IPO surged from $135 to nearly $160, marking a nearly 20% increase, which demonstrates strong demand in the space sector and could positively influence upcoming IPOs for AI companies.
- Airline Stocks Benefit: With falling oil prices, shares of United Airlines, American Airlines, and Southwest Airlines all rose over 3%, suggesting that airlines may improve profitability amid lower costs, thereby enhancing investor confidence.
See More
- Market Rebound: The S&P 500 index rose by 0.29%, the Dow Jones Industrial Average by 0.37%, and the Nasdaq 100 by 0.41%, reflecting market optimism regarding a potential US-Iran peace agreement that could end military hostilities and reopen oil exports through the Strait of Hormuz.
- Consumer Confidence Boost: The University of Michigan's Consumer Sentiment index increased by 4.1 to 48.9, surpassing expectations of 46.0, indicating a rise in consumer confidence that could stimulate spending and drive economic growth.
- SpaceX IPO Performance: SpaceX successfully raised a record $75 billion in its IPO on Thursday, with shares expected to open significantly above the $135 IPO price, suggesting strong demand that could enhance investor sentiment and pave the way for upcoming AI company IPOs.
- Bond Market Pressure: Despite falling oil prices, the 10-year T-note yield rose to 4.493%, reflecting market concerns over inflation pressures, particularly after the reopening of the Strait of Hormuz, which may influence future monetary policy decisions.
See More
- Market Movements: The S&P 500 Index is down 0.31%, while the Dow Jones Industrial Average is up 0.09%, and the Nasdaq 100 Index is down 0.53%, indicating cautious investor sentiment amid expectations of a US-Iran peace agreement.
- Oil Price Reaction: WTI crude oil prices have fallen over 1% on optimism surrounding a potential US-Iran agreement, which could lead to the reopening of the Strait of Hormuz, thereby impacting global oil supply chains and increasing market uncertainty.
- Consumer Confidence Rise: The University of Michigan's Consumer Sentiment Index rose by 4.1 to 48.9, surpassing the expected increase to 46.0, suggesting improved consumer confidence that could drive future spending.
- SpaceX IPO Performance: SpaceX successfully went public on Thursday, raising a record $75 billion, with shares expected to open significantly above the IPO price of $135, indicating strong market demand that may positively influence upcoming IPOs for AI companies.
See More










